Alignment Healthcare (NASDAQ: ALHC) recently received a number of ratings updates from brokerages and research firms:
- 5/9/2026 – Alignment Healthcare was upgraded by Wall Street Zen from “hold” to “buy”.
- 5/7/2026 – Alignment Healthcare was upgraded by Weiss Ratings from “sell (d-)” to “hold (c-)”.
- 5/7/2026 – Alignment Healthcare was given a new $22.00 price target by Raymond James Financial, Inc..
- 5/1/2026 – Alignment Healthcare had its price target raised by UBS Group AG from $21.00 to $22.00. They now have a “neutral” rating on the stock.
- 5/1/2026 – Alignment Healthcare had its price target raised by Barclays PLC from $18.00 to $19.00. They now have an “equal weight” rating on the stock.
- 4/28/2026 – Alignment Healthcare was upgraded by Zacks Research from “hold” to “strong-buy”.
- 4/20/2026 – Alignment Healthcare had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 4/17/2026 – Alignment Healthcare is now covered by Wolfe Research. They set an “outperform” rating and a $24.00 price target on the stock.
Insider Buying and Selling at Alignment Healthcare
In other Alignment Healthcare news, President Dawn Christine Maroney sold 36,749 shares of the company’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $17.84, for a total value of $655,602.16. Following the completion of the transaction, the president owned 1,058,813 shares in the company, valued at approximately $18,889,223.92. This represents a 3.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John E. Kao sold 298,000 shares of Alignment Healthcare stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $16.89, for a total value of $5,033,220.00. Following the sale, the chief executive officer directly owned 1,508,641 shares in the company, valued at approximately $25,480,946.49. This trade represents a 16.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,569,859 shares of company stock valued at $29,569,358. Corporate insiders own 5.20% of the company’s stock.
At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.
Featured Stories
- Five stocks we like better than Alignment Healthcare
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
- 3 AI Data Center Stocks Worth Watching for Capital Rotation
- McDonald’s Is the Cheapest It’s Been in Years—Does That Make It a Buy?
- Karman: Defense Darling’s Outlook Strengthens After 40% Drop
Receive News & Ratings for Alignment Healthcare Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alignment Healthcare Inc and related companies with MarketBeat.com's FREE daily email newsletter.
